查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015128

口服蛋白質和胜肽市場：按產品類型、配方、開發階段、應用和最終用戶分類的全球市場預測 – 2026-2032 年

Oral Proteins & Peptides Market by Product Type, Formulation, Development Stage, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，口服蛋白質和胜肽市場價值將達到 27.3 億美元，到 2026 年將成長至 28.6 億美元，到 2032 年將達到 39.9 億美元，複合年成長率為 5.57%。

主要市場統計數據
基準年 2025 27.3億美元
預計年份：2026年 28.6億美元
預測年份 2032 39.9億美元
複合年成長率 (%) 5.57%

全面概述口服蛋白質和胜肽療法如何重新定義整個醫療保健系統的臨床給藥模式和商業策略。

蛋白質和胜肽的口服給藥代表著治療方法的重大變革，它重塑了臨床醫生、患者和相關人員對生物製藥治療途徑的認知。近年來，技術的進步克服了酵素分解、上皮細胞滲透性和生物利用度差異等障礙，使以往只能注射給藥的分子轉變為口服給藥的候選藥物。因此，研發人員正在探索融合化學、器械工程和藥物科學的多樣化製劑策略和遞送平台，以實現患者偏好的給藥途徑，並擴大生物製藥的治療範圍。

科學、監管和商業方面的關鍵轉折點正在加速從注射型生物製藥向患者更青睞的口服製劑的轉變。

隨著科學界、監管界和商業界各方力量的匯聚，口服蛋白質和胜肽類藥物領域正經歷一系列變化。首先，吸收促進劑、蛋白酶抑制劑和載體技術的進步顯著提高了某些胜肽類藥物的口服生物有效性度，使得以往只能透過腸外途徑給藥的分子能夠被重新設計用於口服。除了製劑化學之外，腸溶包衣和奈米顆粒系統的進步也提高了藥物在胃腸道中的穩定性，從而增加了長期口服給藥方案的可行性。

2025 年實施的貿易政策轉變如何促進了口服生技藥品。

2025年實施的貿易政策調整為口服蛋白和胜肽類藥物的生產商和經銷商帶來了新的營運和策略複雜性。關稅變化導致關鍵原料（包括添加劑、高級配方成分和專用包裝材料）的到貨成本波動。因此，籌資策略轉向優先考慮供應商多元化和區域採購，以減輕單一國家關稅的影響並降低原物料價格波動的風險。

以細分為主導的框架，將產品類型、配方選擇、臨床開發階段、治療應用和最終用戶管道與策略決策連結起來。

深入的市場區隔揭示了科學進步與商業性機會的交匯點，使企業領導者能夠將投資和研發重點與患者需求和市場可行性相匹配。根據產品類型，市場可細分為胰島素相關蛋白質療法和胜肽療法。胰島素相關蛋白質療法包括胰島素組合藥物、長效胰島素類似物、速效胰島素類似物和重組人類胰島素，每種產品都面臨與酵素穩定性和吸收動力學相關的獨特製劑和給藥挑戰。胜肽類療法包括抑鈣素相關療法、Glucagon-Like Peptide-1受體促效劑和血管加壓素類似物，其分子大小、受體藥理和標靶適應症會影響口服給藥的可行性。

美洲、歐洲、中東和非洲以及亞太地區的戰略區域趨勢和市場准入方面的細微差異決定了口服生技藥品的准入和市場規模。

區域趨勢影響口服蛋白和胜肽製劑的臨床試驗進展、生產重點、監管互動和商業化策略，了解這些趨勢對於有效進入市場至關重要。在美洲，創新中心和一體化醫療保健系統為早期採用以患者為中心的給藥模式創造了有利環境。雖然現有的監管管道提供了可預測的互動，但也需要全面的真實世界數據來支援廣泛的保險報銷。因此，企業通常會在該地區試點藥物依從性計劃和基於價值的合約框架，以證明其能夠降低後續成本並改善治療效果。

企業策略、夥伴關係和營運選擇如何協調一致，以降低開發風險並加速口服胜肽和蛋白質療法的商業化？

口服蛋白和胜肽類藥物領域的公司正在採取多種策略來降低研發風險並加速商業化進程。一些公司專注於開發專有製劑平台，以實現多種胜肽類藥物的口服生物有效性度，並尋求許可和平台合作來實現技術商業化。另一些公司則優先考慮臨床和生產能力的緊密整合，以確保從早期藥物動力學驗證到規模化商業化生產的無縫銜接。在整個生態系統中，與合約研發生產力機構（CDMO）合作正成為通用策略。

領導者應實施哪些可操作的策略重點和營運措施，才能將口服生物製劑創新轉化為永續的商業性成功。

產業領導者應優先採取一系列切實可行的步驟，將技術潛力轉化為永續的商業性成果。首先，將製劑和器材開發與早期臨床試驗設計結合，確保將藥物動力學和依從性目標納入關鍵試驗終點。這種協調一致可以減少研發迭代，並提高支付方在評估相對價值時所期望的證據的連續性。其次，透過供應商多元化、選擇區域製造合作夥伴以及模組化生產策略，將供應鏈韌性制度化，從而能夠根據不斷變化的市場需求重新分配產能。

我們採用透明的混合方法，結合專家訪談、跨部門研討會和情境分析，確保獲得可操作且引人注目的見解。

本分析整合了嚴謹調查方法進行的一手和二手研究，以確保結果的可重複性和策略有效性。研究途徑結合了對製劑科學、臨床開發、法規事務、生產製造和商業運營等領域專家的結構化訪談。這些定性研究結果與公開的監管指南、同行評審文獻和公司資訊披露進行交叉比對，以檢驗技術論點並推斷行業對政策變化的應對措施。

本文簡明扼要地總結了為什麼整合科學、營運和商業性合作對於實現口服生物製藥的臨床和經濟潛力至關重要。

在藥物科學進步、監管政策明確以及患者和支付方期望不斷變化等因素的推動下，口服蛋白質和胜肽製劑正從概念階段邁向具體的臨床和商業性現實。這些趨勢在為創新創造有利環境的同時，也對組織敏捷性、供應鏈設計和實證實踐提出了新的要求。能夠取得成功的組織，將是那些能夠及早整合跨學科專業知識、建立夥伴關係以彌補能力差距，並將研發策略與切實可行的市場進入計劃相結合的組織。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 口服蛋白質與胜肽市場：依產品類型分類

  • 胰島素相關蛋白
    • 含胰島素的製劑
    • 長效胰島素類似物
    • 速效胰島素類似物
    • 重組人類胰島素
  • 胜肽類藥物
    • 以抑鈣素的藥物
    • Glucagon-Like Peptide-1受體促效劑
    • 血管加壓素類似物

第9章 按劑型分類的口服蛋白質和胜肽市場

  • 膠囊製劑
  • 液體
  • 粉末製劑
  • 片劑配方

第10章：口服蛋白質和胜肽市場依發展階段分類

  • 第一階段和第二階段臨床試驗
  • III期臨床試驗
  • 上市後監測
  • 臨床前試驗

第11章 口服蛋白質與胜肽市場：依應用分類

  • 癌症治療
  • 心血管疾病
  • 糖尿病管理
  • 內分泌疾病

第12章 口服蛋白質與胜肽市場：依最終用戶分類

  • 居家醫療設施
  • 醫院和診所
  • 研究機構
  • 專科診所

第13章 口服蛋白質與胜肽市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口服蛋白質與胜肽市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 口服蛋白質與胜肽市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國口服蛋白質與胜肽市場

第17章：中國口服蛋白和胜肽市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi SA
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market was valued at USD 2.73 billion in 2025 and is projected to grow to USD 2.86 billion in 2026, with a CAGR of 5.57%, reaching USD 3.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.73 billion
Estimated Year [2026] USD 2.86 billion
Forecast Year [2032] USD 3.99 billion
CAGR (%) 5.57%

A comprehensive orientation to how oral protein and peptide therapeutics are redefining clinical delivery models and commercial strategies across healthcare systems

Oral delivery of proteins and peptides represents a pivotal evolution in therapeutic modalities, reshaping how clinicians, patients, and industry stakeholders conceive of biologic treatment pathways. Recent technological advances have transformed molecules that were once strictly injectable into candidates for oral administration by addressing barriers such as enzymatic degradation, epithelial permeability, and inconsistent bioavailability. Consequently, developers have pursued a range of formulation strategies and delivery platforms that converge across chemistry, device engineering, and formulation science to unlock patient-preferred routes of administration and broaden the therapeutic footprint of biologics.

As the landscape matures, regulatory authorities and payers are increasingly attuned to the differentiated value propositions that oral proteins and peptides bring to chronic disease management, oncology supportive care, and hormonal therapies. This shift influences investment priorities, partnership strategies, and clinical development pathways. Importantly, the clinical and commercial potential hinges not only on molecular innovation but also on scalable manufacturing, validated pharmacokinetic performance, and reproducible real-world adherence outcomes. Taken together, these elements define a complex ecosystem in which scientific promise must align with commercial feasibility.

This executive summary synthesizes strategic inflection points, segmentation-driven insights, regional dynamics, corporate approaches, and pragmatic recommendations to guide leaders who must make time-sensitive decisions about pipeline prioritization, channel development, and manufacturing footprints. By focusing on actionable intelligence and rigorous methodological transparency, the analysis supports stakeholders seeking to navigate regulatory complexity, optimize product portfolios, and accelerate patient access across diverse care settings.

High-impact scientific, regulatory, and commercial inflection points that are accelerating the transition of injectable biologics to patient-preferred oral formats

The landscape for orally delivered proteins and peptides is undergoing a set of transformative shifts driven by converging scientific, regulatory, and commercial forces. First, advances in absorption enhancers, protease inhibitors, and carrier technologies have materially improved oral bioavailability for select peptide classes, enabling molecules previously constrained to parenteral routes to be reimagined for oral dosing. Alongside formulation chemistry, progress in enteric coatings and nanoparticulate systems has enhanced stability through the gastrointestinal tract, thereby increasing the feasibility of chronic oral regimens.

Simultaneously, regulatory frameworks are evolving to accommodate novel modalities and combination products. Regulatory agencies are clarifying pathways for demonstrating bioequivalence, safety margins, and device-drug co-development, which reduces uncertainty for sponsors and accelerates development timelines when aligned early. Payer conversations are also intensifying around the long-term value delivered by oral biologics, particularly when oral dosing demonstrably improves adherence, reduces clinic visits, and mitigates injection-related adverse events.

Commercially, stakeholder expectations are shifting. Patients and providers increasingly prioritize convenience and quality of life, while health systems scrutinize total cost of care. These drivers incentivize strategic partnerships between specialty biotechnology firms, contract development and manufacturing organizations, and the larger pharmaceutical ecosystem to bridge capabilities in clinical development, scalable manufacturing, and global distribution. Finally, the competitive landscape is being reshaped by the emergence of oral formulations targeting chronic indications, where the potential for broad uptake is high and where effective patient support programs and channel strategies will determine winner-take-share dynamics.

How trade policy shifts implemented in 2025 catalyzed supply chain reconfiguration, sourcing diversification, and strategic contracting across the oral biologics value chain

Trade policy adjustments enacted in 2025 introduced a new layer of operational and strategic complexity for manufacturers and distributors engaged in oral proteins and peptides. Tariff changes altered landed costs across critical inputs including excipients, advanced formulation components, and specialized packaging materials. As a consequence, procurement strategies shifted to prioritize supplier diversification and regional sourcing to reduce exposure to single-country tariffs and mitigate volatility in input pricing.

Manufacturers responded by reassessing global manufacturing footprints and accelerating conversations about nearshoring and multi-site redundancy. These decisions were influenced not only by cost considerations but also by lead-time reliability, regulatory harmonization across jurisdictions, and the need to preserve uninterrupted supply for chronic therapies. Contract manufacturing organizations experienced renewed demand as companies sought flexible capacity that could be deployed across geographies without triggering additional trade frictions.

In parallel, the tariff environment influenced partnership structures and commercial contracting. Organizations increasingly embedded tariff contingencies into supplier contracts and pricing models, and some adopted hedging strategies that insulated margins from short-term trade disruptions. Payers and integrated delivery networks also recalibrated procurement expectations, anticipating potential price pass-through effects and seeking risk-sharing arrangements that stabilized access for patients.

Importantly, the tariffs accelerated investment in component standardization and process optimization to reduce cost per dose and strengthen supply chain resilience. R&D budgets were rebalanced in some organizations to prioritize process intensification and formulation robustness, thereby reducing dependence on scarce or tariff-sensitive inputs. Overall, the cumulative impact of tariff policy in 2025 catalyzed strategic moves toward supply chain agility, collaborative manufacturing models, and contract structures designed to preserve market access and pricing stability in a more uncertain trade environment.

A segmentation-driven framework that connects product types, formulation choices, clinical development stages, therapeutic applications, and end-user channels to strategic decision-making

Insightful segmentation illuminates where scientific advances and commercial opportunities intersect, enabling leaders to align investments and development priorities with patient needs and canal feasibility. Based on product type, the market divides into insulin-based proteins and peptide therapeutics. The insulin-based proteins category includes combination insulin products, long-acting insulin analogues, rapid-acting insulin analogues, and recombinant human insulin, each presenting distinct formulation and delivery challenges tied to enzymatic stability and absorption kinetics. The peptide therapeutics category encompasses calcitonin-based therapies, glucagon-like peptide-1 receptor agonists, and vasopressin analogs, where molecular size, receptor pharmacology, and target indication shape feasibility for oral administration.

Based on formulation, the market spans capsule formulations, liquid formulations, powder formulations, and tablet formulations, and each format imposes trade-offs between stability, dose uniformity, manufacturability, and patient convenience. Developers must evaluate these trade-offs in the context of intended dosing frequency, target population, and distribution model. Based on development stage, the market includes Phase I & II clinical trials, Phase III clinical trials, post-market surveillance, and preclinical studies, reflecting a continuum where translational hurdles at early stages can materially affect later-stage commercialization pathways and risk profiles.

Based on application, the market targets cancer treatment, cardiovascular diseases, diabetes management, and hormonal disorders, with each therapeutic area presenting unique regulatory expectations, clinical endpoints, and payer evidence requirements. Developers should tailor clinical programs and value dossiers to the specific evidentiary demands of these indications. Based on end-user, the market serves home care settings, hospitals and clinics, research laboratories, and specialty clinics, which influences distribution strategies, patient support programs, and device design considerations to ensure adherence and patient safety outside traditional clinical settings.

Integrating segmentation perspectives highlights that portfolio decisions cannot be made in isolation; product type dictates formulation feasibility, while development stage dictates evidentiary requirements and time to access. Applications determine payer dialogue and clinical endpoint selection, and end-user considerations drive packaging, patient support, and distribution models. Leaders must therefore apply segmentation-driven lenses to align R&D, manufacturing, regulatory, and commercial teams toward coherent product strategies.

Strategic regional dynamics and go-to-market nuances across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access and scale for oral biologics

Regional dynamics shape the clinical trial landscape, manufacturing priorities, regulatory interactions, and commercialization strategies for oral proteins and peptides, and understanding these contours is essential for effective market entry. In the Americas, innovation hubs and integrated health systems create fertile conditions for early adoption of patient-centric delivery models, while established regulatory pathways offer predictable interactions but also require comprehensive real-world evidence to support broad reimbursement. As a result, companies often pilot adherence programs and value-based contracting frameworks in this region to demonstrate downstream cost offsets and improved outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory environments and varied payer architectures necessitate differentiated market access strategies. This region demands adaptive regulatory engagement, selective country launches informed by local clinical practice patterns, and partnership approaches that leverage regional manufacturing or distribution partners to navigate importation and reimbursement complexity. Moreover, public health priorities and procurement frameworks can accelerate uptake in settings where oral delivery reduces clinic burden and supports decentralized care.

In the Asia-Pacific region, rapid adoption of novel therapeutics, strong manufacturing capacity, and growing local biotech ecosystems make it an important theater for both clinical development and scaled manufacturing. Regulatory authorities across the region are increasingly open to innovative trial designs and collaborative review processes, yet local market dynamics such as pricing pressure and competitive generics markets influence commercialization tactics. Consequently, strategic entry often combines clinical partnerships, local manufacturing or tolling arrangements, and tailored patient support programs that reflect regional care delivery models and payer expectations.

Collectively, regional insights underscore the need for geographically nuanced strategies that balance global regulatory alignment with local commercialization realities. Organizations that tailor their clinical programs, supply chain architecture, and reimbursement engagement to the specific characteristics of each region will be better positioned to convert clinical innovation into sustained patient access.

How corporate strategies, partnerships, and operational choices are aligning to derisk development and accelerate commercialization of oral peptide and protein therapeutics

Companies operating in the oral proteins and peptides domain are pursuing diverse strategies to de-risk development and accelerate commercialization. Some firms concentrate on proprietary formulation platforms that enable oral bioavailability across multiple peptide classes and therefore pursue licensing and platform partnerships to monetize their technology. Others prioritize tight integration of clinical and manufacturing capabilities to ensure a seamless path from early-phase demonstration of pharmacokinetics to scale-up for commercial production. Across the ecosystem, collaboration with contract development and manufacturing organizations has emerged as a common strategy to secure flexible capacity without incurring large capital expenditures.

Strategic alliances extend beyond manufacturing to include distribution partners, specialty pharmacies, and digital therapeutics vendors that can bolster adherence and real-world monitoring. Companies are also investing in evidence generation that aligns with payer value frameworks, including longitudinal adherence studies, health economics analyses, and comparator trials that highlight differential benefits of oral administration. In parallel, some organizations direct resources to improving supply chain resilience through multi-sourcing strategies and qualification of alternate excipient suppliers to mitigate disruption risk.

R&D pipelines reflect a spectrum of focus areas, from insulin analogues repurposed for oral dosing to peptide receptor agonists aimed at chronic metabolic and cardiovascular indications. Firms that pair robust clinical development programs with early payer engagement and clear manufacturing scale plans tend to accelerate path-to-reimbursement and market uptake. Finally, leadership teams are increasingly emphasizing regulatory foresight, embedding regulatory science expertise early in development to navigate combination product pathways, bioavailability challenges, and post-market surveillance obligations that accompany novel oral biologic formulations.

Actionable strategic priorities and operational levers that leaders must implement to convert oral biologic innovation into enduring commercial success

Industry leaders should prioritize a set of actionable steps that convert technical promise into sustainable commercial performance. First, integrate formulation and device development with early clinical trial design to ensure that pharmacokinetic and adherence objectives are embedded into pivotal study endpoints. This alignment reduces development iterations and improves the evidentiary continuity payers expect when assessing comparative value. Second, institutionalize supply chain resilience through supplier diversification, qualification of regional manufacturing partners, and modular production strategies that allow capacity redeployment as market demand evolves.

Third, begin payer and health system engagement early, using real-world demonstration projects to quantify adherence benefits and downstream resource offsets attributable to oral delivery. Early value conversations will smooth market access pathways and inform pricing strategies that reflect total cost of care. Fourth, structure partnerships that complement internal capabilities rather than duplicate them; selective licensing of platform technologies or co-development arrangements with established formulation specialists can accelerate timelines while preserving strategic control over core assets.

Fifth, invest in post-market evidence platforms that capture adherence, patient-reported outcomes, and pharmacovigilance data in decentralized settings. Such investments will support regulatory commitments and enrich the value proposition presented to payers and providers. Finally, adopt a staged regional deployment strategy that sequences launches to balance regulatory complexity, manufacturing capacity, and commercial readiness, thereby protecting margins while maximizing learnings for subsequent market entries.

A transparent mixed-methods research approach combining expert interviews, cross-functional workshops, and scenario analysis to ensure actionable and defensible insights

This analysis synthesizes primary and secondary research conducted under rigorous methodological standards to ensure reproducibility and strategic relevance. The research approach combined structured interviews with subject matter experts across formulation science, clinical development, regulatory affairs, manufacturing, and commercial operations. These qualitative insights were triangulated with publicly available regulatory guidance, peer-reviewed literature, and company disclosures to validate technical claims and infer likely industry responses to policy shifts.

Analytical methods included cross-functional workshops to map value chain dependencies, scenario planning to assess the impact of trade and regulatory volatility, and comparative case analyses of oral formulation programs across therapeutic areas. Where appropriate, assumptions were stress-tested through sensitivity analyses focused on key development and supply chain variables such as formulation success probability, manufacturing lead times, and post-approval surveillance requirements. The study also incorporated a limitations section that explicitly acknowledges areas of residual uncertainty, including long-term adherence behavior in real-world settings and evolving regulatory interpretations for novel delivery technologies.

Ethical protocols guided all primary research, ensuring informed consent, confidentiality, and the anonymization of proprietary insights. Finally, findings were peer-reviewed internally by multidisciplinary experts to ensure analytic rigor and practical applicability for stakeholders considering investments, partnerships, or portfolio reprioritization in oral proteins and peptides.

Concise synthesis of why integrated scientific, operational, and commercial alignment is essential for realizing the clinical and economic promise of oral biologic therapies

Oral proteins and peptides are moving from conceptual promise toward tangible clinical and commercial reality, propelled by advances in formulation science, shifting regulatory clarity, and evolving patient and payer expectations. These dynamics create a fertile environment for innovation but also impose new demands on organizational agility, supply chain design, and evidence generation. Success will favor organizations that integrate cross-disciplinary expertise early, structure partnerships to fill capability gaps, and align development strategies with pragmatic market access planning.

The interplay between product type, formulation path, development stage, application area, and end-user setting underscores the importance of segmentation-aware decision-making. Regional nuances further compel tailored strategies that balance global ambitions with local operational readiness. Importantly, recent trade policy adjustments have underscored the fragility of input-dependent value chains, accelerating moves toward diversified sourcing and regional capacity.

In sum, stakeholders who adopt an integrated approach-one that synchronizes scientific validation, manufacturing scalability, regulatory foresight, and payer-focused evidence development-will be best positioned to translate oral biologic advances into improved patient outcomes and durable commercial performance. The imperative now is to act with speed, precision, and collaborative intent to capture the window of opportunity that this therapeutic evolution presents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Proteins & Peptides Market, by Product Type

  • 8.1. Insulin-Based Proteins
    • 8.1.1. Combination Insulin Products
    • 8.1.2. Long-Acting Insulin Analogues
    • 8.1.3. Rapid-Acting Insulin Analogues
    • 8.1.4. Recombinant Human Insulin
  • 8.2. Peptide Therapeutics
    • 8.2.1. Calcitonin-Based Therapies
    • 8.2.2. Glucagon-Like Peptide-1 Receptor Agonists
    • 8.2.3. Vasopressin Analogs

9. Oral Proteins & Peptides Market, by Formulation

  • 9.1. Capsule Formulations
  • 9.2. Liquid Formulations
  • 9.3. Powder Formulations
  • 9.4. Tablet Formulations

10. Oral Proteins & Peptides Market, by Development Stage

  • 10.1. Phase I & II Clinical Trials
  • 10.2. Phase III Clinical Trials
  • 10.3. Post-Market Surveillance
  • 10.4. Preclinical Studies

11. Oral Proteins & Peptides Market, by Application

  • 11.1. Cancer Treatment
  • 11.2. Cardiovascular Diseases
  • 11.3. Diabetes Management
  • 11.4. Hormonal Disorders

12. Oral Proteins & Peptides Market, by End-User

  • 12.1. Home Care Settings
  • 12.2. Hospitals & Clinics
  • 12.3. Research Laboratories
  • 12.4. Specialty Clinics

13. Oral Proteins & Peptides Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Proteins & Peptides Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Proteins & Peptides Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Proteins & Peptides Market

17. China Oral Proteins & Peptides Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Amryt Pharma plc
  • 18.8. Astellas Pharma Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Biocon Limited
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Catalent, Inc.
  • 18.13. Entera Bio Ltd. by DNA Biomedical Solutions
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • 18.16. Johnson & Johnson Services, Inc.
  • 18.17. Merck KGaA
  • 18.18. Novartis AG
  • 18.19. Novo Nordisk A/S
  • 18.20. Oramed Pharmaceuticals Inc.
  • 18.21. PeptiDream Inc.
  • 18.22. Pfizer, Inc.
  • 18.23. Protagonist Therapeutics, Inc.
  • 18.24. Proxima Concepts Limited
  • 18.25. Rani Therapeutics, LLC
  • 18.26. Sanofi S.A.
  • 18.27. Tarsa Therapeutics, Inc.
  • 18.28. Teva Pharmaceutical Industries Ltd.
  • 18.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)